Carl W. Langren's Insider Trades & SAST Disclosures

Carl W. Langren's most recent trade in Lumos Pharma Inc was a trade of 683 Common Stock done at an average price of $12.3 . Disclosure was reported to the exchange on April 1, 2021.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Lumos Pharma Inc
Carl W. Langren Chief Financial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.25 per share. 01 Apr 2021 683 11,494 (0%) 0% 12.3 8,367 Common Stock
Lumos Pharma Inc
Carl W. Langren Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2021 11,475 11,475 - - Stock Option (Right to Buy)
Lumos Pharma Inc
Carl W. Langren Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2021 939 12,177 (0%) 0% 0 Common Stock
Lumos Pharma Inc
Carl W. Langren Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2020 45,000 45,000 - - Stock Option (Right to Buy)
Lumos Pharma Inc
Carl W. Langren Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2020 9,000 11,238 (0%) 0% 0 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades